📊 AUPH Key Takeaways
Is Aurinia Pharmaceuticals Inc. (AUPH) a Good Investment?
Aurinia demonstrates exceptional profitability with 101.5% net margin and 37.1% operating margin, driven by 20.4% revenue growth to $283.1M. The company maintains fortress-like balance sheet strength with 5.25x current ratio, zero debt, and robust free cash flow generation of $135.7M (47.9% FCF margin), though the extraordinary 4893% net income growth warrants verification for non-recurring items or one-time gains.
Aurinia shows strong underlying fundamentals with double-digit revenue growth, high operating profitability, and robust free cash flow generation. The balance sheet is exceptionally healthy, with no meaningful leverage and strong liquidity, although the outsized net income and net margin suggest at least part of recent earnings strength may be driven by non-recurring or below-the-line items.
Why Buy Aurinia Pharmaceuticals Inc. Stock? AUPH Key Strengths
- Exceptional profitability metrics: 101.5% net margin and 37.1% operating margin far exceed pharmaceutical sector averages
- Strong revenue growth of 20.4% YoY in competitive pharma sector
- Fortress balance sheet with zero debt, $80.2M cash, and 5.25x current ratio providing financial flexibility
- Outstanding cash generation with $135.7M operating cash flow and 47.9% FCF margin
- High return on equity (49.4%) and ROA (38.2%) indicating efficient capital deployment
- Minimal liquidity risk with 4.76x quick ratio and strong interest coverage of 42.3x
- Revenue growth remains solid at 20.4% year over year, indicating continued commercial momentum.
- Operating margin of 37.1% and free cash flow margin of 47.9% point to strong operating efficiency and cash conversion.
- Balance sheet strength is high, with a 5.25x current ratio, substantial cash, and effectively no long-term debt.
AUPH Stock Risks: Aurinia Pharmaceuticals Inc. Investment Risks
- Extraordinary net income increase of 4893% YoY suggests material one-time gains, asset sales, or tax benefits requiring audit trail verification
- Pharmaceutical sector faces regulatory, patent cliff, and drug development execution risks not fully captured in trailing data
- Net margin of 101.5% (exceeding 100%) is unsustainable and indicates potential data anomalies or accounting items requiring clarification
- Significant insider trading activity (16 Form 4 filings in 90 days) warrants monitoring for potential information asymmetries
- Limited visibility into R&D pipeline productivity and clinical trial success rates from provided fundamentals
- Missing gross margin data and capex information limits operational efficiency assessment
- Net income growth far exceeds revenue growth, which raises concern that recent earnings may include one-time gains and may not fully reflect recurring profitability.
- The absence of gross margin and capital expenditure detail limits visibility into core product economics and reinvestment needs.
- As a pharmaceutical company, fundamentals may be vulnerable to product concentration, regulatory outcomes, and commercialization execution.
Key Metrics to Watch
- Verification of non-operating income/one-time gains explaining 4893% net income growth
- Gross margin expansion or maintenance with revenue scale
- Operating cash flow sustainability relative to reported net income
- Research and development spend trends and pipeline advancement
- Revenue composition by product line and geographic segment
- Insider trading patterns and insider holding trends
- Sustainable operating income and operating margin excluding one-time items
- Revenue growth and operating cash flow consistency over the next few filings
Aurinia Pharmaceuticals Inc. (AUPH) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The 47.9% free cash flow margin provides substantial flexibility for dividends, buybacks, and strategic investments. Strong liquidity with a 5.25x current ratio provides a solid financial cushion.
AUPH Profit Margin, ROE & Profitability Analysis
AUPH vs Healthcare Sector: How Aurinia Pharmaceuticals Inc. Compares
How Aurinia Pharmaceuticals Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Aurinia Pharmaceuticals Inc. Stock Overvalued? AUPH Valuation Analysis 2026
Based on fundamental analysis, Aurinia Pharmaceuticals Inc. appears fundamentally strong relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Aurinia Pharmaceuticals Inc. Balance Sheet: AUPH Debt, Cash & Liquidity
AUPH Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Aurinia Pharmaceuticals Inc.'s revenue has grown significantly by 465% over the 5-year period, indicating strong business expansion. The most recent EPS of $-0.54 indicates the company is currently unprofitable.
AUPH Revenue Growth, EPS Growth & YoY Performance
AUPH Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $67.8M | $722.0K | $0.03 |
| Q2 2025 | $57.2M | $722.0K | $0.01 |
| Q1 2025 | $50.3M | -$10.7M | $-0.07 |
| Q3 2024 | $54.5M | $4.3M | $0.03 |
| Q2 2024 | $41.5M | $722.0K | $0.01 |
| Q1 2024 | $34.4M | -$10.7M | $-0.07 |
| Q3 2023 | $54.5M | -$9.0M | $-0.06 |
| Q2 2023 | $28.2M | -$11.5M | $-0.08 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Aurinia Pharmaceuticals Inc. Dividends, Buybacks & Capital Allocation
AUPH SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Aurinia Pharmaceuticals Inc. (CIK: 0001600620)
📋 Recent SEC Filings
❓ Frequently Asked Questions about AUPH
What is the AI rating for AUPH?
Aurinia Pharmaceuticals Inc. (AUPH) has a Combined AI Rating of BUY from Claude (BUY) and ChatGPT (BUY) with 76% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are AUPH's key strengths?
Claude: Exceptional profitability metrics: 101.5% net margin and 37.1% operating margin far exceed pharmaceutical sector averages. Strong revenue growth of 20.4% YoY in competitive pharma sector. ChatGPT: Revenue growth remains solid at 20.4% year over year, indicating continued commercial momentum.. Operating margin of 37.1% and free cash flow margin of 47.9% point to strong operating efficiency and cash conversion..
What are the risks of investing in AUPH?
Claude: Extraordinary net income increase of 4893% YoY suggests material one-time gains, asset sales, or tax benefits requiring audit trail verification. Pharmaceutical sector faces regulatory, patent cliff, and drug development execution risks not fully captured in trailing data. ChatGPT: Net income growth far exceeds revenue growth, which raises concern that recent earnings may include one-time gains and may not fully reflect recurring profitability.. The absence of gross margin and capital expenditure detail limits visibility into core product economics and reinvestment needs..
What is AUPH's revenue and growth?
Aurinia Pharmaceuticals Inc. reported revenue of $283.1M.
Does AUPH pay dividends?
Aurinia Pharmaceuticals Inc. does not currently pay dividends.
Where can I find AUPH SEC filings?
Official SEC filings for Aurinia Pharmaceuticals Inc. (CIK: 0001600620) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is AUPH's EPS?
Aurinia Pharmaceuticals Inc. has a diluted EPS of $2.07.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is AUPH a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Aurinia Pharmaceuticals Inc. has a BUY rating with 76% confidence. The AI analysis suggests favorable fundamentals based on SEC filings. This is not investment advice.
Is AUPH stock overvalued or undervalued?
Valuation metrics for AUPH: ROE of 49.4% (sector avg: 15%), net margin of 101.5% (sector avg: 12%). Higher ROE suggests strong returns relative to peers.
Should I buy AUPH stock in 2026?
Our dual AI analysis gives Aurinia Pharmaceuticals Inc. a combined BUY rating for 2026. Revenue is data pending, with profitability above sector average. Always conduct your own research.
What is AUPH's free cash flow?
Aurinia Pharmaceuticals Inc.'s operating cash flow is $135.7M, with capital expenditures of N/A. FCF margin is 47.9%.
How does AUPH compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin 101.5% (avg: 12%), ROE 49.4% (avg: 15%), current ratio 5.25 (avg: 2).
Why is AUPH's return on equity (ROE) so high?
Aurinia Pharmaceuticals Inc. has a return on equity of 49.4%, significantly above the Healthcare sector average of 15%. A high ROE indicates the company is efficient at generating profits from shareholder equity. This is supported by a 101.5% net margin.